Patents Assigned to Lixte Biotechnology, Inc.
  • PROTEIN PHOSPHATASE 2A INHIBITORS FOR TREATING MYELODYSPLASTIC SYNDROMES
    Publication number: 20170340628
    Abstract: Disclosed are methods for treating a myelodysplastic syndrome (MDS) in a subject that involves administering to the subject a therapeutically effective amount of a protein phosphatase 2A (PP2A) inhibitor.
    Type: Application
    Filed: July 23, 2015
    Publication date: November 30, 2017
    Applicants: H. Lee Moffitt Cancer Center and Research Institute, Inc., Lixte Biotechnology, Inc.
    Inventors: Alan F. List, David A. Sallman, John S. Kovach
  • PROCESS OF SYNTHESIZING 3-(4-METHYLPIPERAZINE-1-CARBONYL)-7-OXABICYCLO[2.2.1] HEPTANE-2-CARBOXYLIC ACID
    Publication number: 20170305925
    Abstract: The present invention provides a process for producing the compound having the structure: comprising (a) reacting a compound having the structure: with a compound having the structure: in the presence of a first organic solvent under conditions sufficient to produce the compound, wherein the first organic solvent is a substituted benzene.
    Type: Application
    Filed: October 14, 2015
    Publication date: October 26, 2017
    Applicant: Lixte Biotechnology, Inc.
    Inventors: Jason J. Piotrowski, Dumitru Ionescu
  • METHODS FOR REGULATING CELL MITOSIS BY INHIBITING SERINE/THREONINE PHOSPHATASE
    Publication number: 20170259081
    Abstract: Disclosed herein are methods of inhibiting proliferation of a cancer cell or inducing apoptosis of a cancer cell, which does not overexpress N—CoR. Also disclosed herein are methods of inhibiting proliferation or inducing apoptosis of a cancer cell that overexpresses TCTP and methods for determining whether a compound is effective in inducing cell death.
    Type: Application
    Filed: December 20, 2016
    Publication date: September 14, 2017
    Applicant: LIXTE BIOTECHNOLOGY, INC.
    Inventor: John S. Kovach
  • SANGUINARINE ANALOG PP2C INHIBITORS FOR CANCER TREATMENT
    Publication number: 20170240558
    Abstract: Sanguinarine analogs as PP2C inhibitors are disclosed for the treatment of various cancers, as well as methods of synthesizing such analogs.
    Type: Application
    Filed: May 8, 2017
    Publication date: August 24, 2017
    Applicant: Lixte Biotechnology, Inc.
    Inventors: John S. KOVACH, Francis JOHNSON, Ramakrishna SAMUDRALA
  • OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES FOR THE TREATMENT OF OVARIAN CANCER
    Publication number: 20170136008
    Abstract: A method of treating ovarian cancer in a subject afflicted therewith comprising administering to the subject an effective amount of an anti-cancer agent and an effective amount of a compound having the structure:
    Type: Application
    Filed: June 19, 2015
    Publication date: May 18, 2017
    Applicants: Lixte Biotechnology, Inc., The United States of America, as Represented by th e Secretary, Department of Health & Human Service
    Inventors: John S. Kovach, Zhengping Zhuang, Ki-eun Chang, Matthew Hall, Michael M. Gottesman
  • OXABICYCLOHEPTANE PRODRUGS
    Publication number: 20160333024
    Abstract: The present invention provides a compound having the structure:
    Type: Application
    Filed: May 13, 2016
    Publication date: November 17, 2016
    Applicant: Lixte Biotechnology, Inc.
    Inventors: JOHN S. KOVACH, ROBERT VOLKMANN, ANTHONY MARFAT
  • OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES FOR THE TREATMENT OF DEPRESSIVE AND STRESS DISORDERS
    Publication number: 20160303115
    Abstract: A method of treating a depressive or stress disorder in a subject afflicted therewith comprising administering to the subject an effective amount of a compound having the structure:
    Type: Application
    Filed: February 19, 2016
    Publication date: October 20, 2016
    Applicants: Lixte Biotechnology, Inc., Institut national de la santé et de la recherche médicale
    Inventors: JOHN S. KOVACH, SALVATORE LECCA, MANUEL MAMELI
  • HUMAN DOSING OF PHOSPHATASE INHIBITOR
    Publication number: 20160074390
    Abstract: The present invention provides a method of inhibiting protein phosphatase 2A (PP2A) in a human subject in need thereof comprising administering to the subject an amount of from 0.1 mg/m2 to 5 mg/m2 of a compound having the structure or a salt, zwitterion, or ester thereof, so as to thereby inhibit protein phosphatase 2A (PP2A) in the subject.
    Type: Application
    Filed: September 11, 2015
    Publication date: March 17, 2016
    Applicant: Lixte Biotechnology, Inc.
    Inventor: JOHN S. KOVACH
  • FORMULATIONS OF OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES
    Publication number: 20160051544
    Abstract: The invention relates to a pharmaceutical composition comprising a protein phosphatase 2A (PP2A) inhibitor and monosodium glutamate.
    Type: Application
    Filed: April 8, 2014
    Publication date: February 25, 2016
    Applicant: Lixte Biotechnology, Inc.
    Inventors: John S. KOVACH, Mickey L. WELLS
  • HDAC INHIBITORS FOR THE TREATMENT OF TRAUMATIC BRAIN INJURY
    Publication number: 20160008336
    Abstract: The present invention provides a method of treating a subject suffering from traumatic brain injury comprising administering to the subject an effective amount of an HDAC inhibitor, structurally represented, thereby treating the subject suffering from traumatic brain injury.
    Type: Application
    Filed: February 27, 2014
    Publication date: January 14, 2016
    Applicant: Lixte Biotechnology, Inc.
    Inventor: John S. KOVACH
  • SANGUINARINE ANALOG PP2C INHIBITORS FOR CANCER TREATMENT
    Publication number: 20160009727
    Abstract: Sanguinarine analogs as PP2C inhibitors are disclosed for the treatment of various cancers, as well as methods of synthesizing such analogs.
    Type: Application
    Filed: February 27, 2014
    Publication date: January 14, 2016
    Applicant: Lixte Biotechnology, Inc.
    Inventors: John S. KOVACH, Francis JOHNSON, Ramakrishna SAMUDRALA
  • Oxabicycloheptanes and oxabicycloheptenes, their preparation and use
    Patent number: 9079917
    Abstract: This invention provides compounds having the structure which may be used for the treatment of tumors.
    Type: Grant
    Filed: July 10, 2014
    Date of Patent: July 14, 2015
    Assignee: LIXTE BIOTECHNOLOGY, INC.
    Inventors: John S. Kovach, Francis Johnson
  • OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES FOR THE TREATMENT OF REPERFUSION INJURY
    Publication number: 20150174123
    Abstract: A method of reducing reperfusion injury in mammalian tissue comprising contacting the tissue with a protein phosphatase 2A (PP2A) inhibitor having the structure:
    Type: Application
    Filed: June 28, 2013
    Publication date: June 25, 2015
    Applicant: Lixte Biotechnology, Inc.
    Inventor: John S. Kovach
  • OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES FOR THE TREATMENT OF DIABETES
    Publication number: 20150148353
    Abstract: A method of increasing the insulin sensitivity of a mammalian cell by contacting the cell with a protein phosphatase 2A (PP2A) inhibitor having the structure:
    Type: Application
    Filed: June 28, 2013
    Publication date: May 28, 2015
    Applicant: LIXTE BIOTECHNOLOGY, INC.
    Inventor: John S. Kovach
  • Oxabicycloheptanes and oxabicycloheptenes, their preparation and use
    Patent number: 8822461
    Abstract: This invention provides compounds having the structure which may be used for the treatment of tumors.
    Type: Grant
    Filed: April 19, 2013
    Date of Patent: September 2, 2014
    Assignee: Lixte Biotechnology, Inc.
    Inventors: John S. Kovach, Francis Johnson
  • USE OF PHOSPHATASE INHIBITORS OR HISTONE DEACETYLASE INHIBITORS TO TREAT DISEASES CHARACTERIZED BY LOSS OF PROTEIN FUNCTION
    Publication number: 20140235649
    Abstract: A method of treating a mammalian subject afflicted with a disease characterized by a loss of protein function caused by a genetic abnormality associated with the disease comprising administering to the subject a therapeutically effective amount of a protein phosphatase 2A inhibitor or a histone deacetylase inhibitor.
    Type: Application
    Filed: May 24, 2012
    Publication date: August 21, 2014
    Applicant: LIXTE BIOTECHNOLOGY, INC.
    Inventors: John S. Kovach, Zhengping Zhuang, Jie Lu, Chunzhang Yang, Russell Lonser
  • OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES, THEIR PREPARATION AND USE
    Publication number: 20130302402
    Abstract: This invention provides compounds having the structure which may be used for the treatment of tumors.
    Type: Application
    Filed: April 19, 2013
    Publication date: November 14, 2013
    Applicant: LIXTE BIOTECHNOLOGY, INC.
    Inventors: John S. KOVACH, Francis JOHNSON
  • Oxabicycloheptanes and oxabicycloheptenes, their preparation and use
    Patent number: 8541458
    Abstract: This invention provides compounds having the structure which may be used for the treatment of tumors.
    Type: Grant
    Filed: June 11, 2012
    Date of Patent: September 24, 2013
    Assignee: Lixte Biotechnology, Inc.
    Inventors: John S. Kovach, Francis Johnson
  • HDAC inhibitors
    Patent number: 8455688
    Abstract: This invention provides the compound having the structure wherein n is 1-10; X is C—R11 or N, wherein R11 is H, OH, SH, F, Cl, SO2R7, NO2, trifluoromethyl, methoxy, or CO—R7, wherein R7 is alkyl, alkenyl, alkynyl, C3-C8 cycloalkyl, or aryl; Z is R2 is H or NR3R4, wherein R3 and R4 are each independently H, C1-C6 alkyl, or C3-C8 cycloalkyl; R5 is OH or SH; and R6, R12, R13, and R14 are each independently H, OH, SH, F, Cl, SO2R15, NO2, trifluoromethyl, methoxy, or CO—R15, wherein R15 is alkyl, alkenyl, alkynyl, C3-C8 cycloalkyl, or aryl, or a salt of the compound, which is useful in the treatment of tumors.
    Type: Grant
    Filed: March 21, 2012
    Date of Patent: June 4, 2013
    Assignee: Lixte Biotechnology, Inc.
    Inventors: John S. Kovach, Francis Johnson
  • Oxabicycloheptanes and oxabicycloheptenes, their preparation and use
    Patent number: 8426444
    Abstract: This invention provides compounds having the structure which may be used for the treatment of tumors.
    Type: Grant
    Filed: June 30, 2011
    Date of Patent: April 23, 2013
    Assignee: Lixte Biotechnology, Inc.
    Inventors: John Kovach, Francis Johnson